Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Increased asprosin is associated with non-alcoholic fatty liver disease in children with obesity
Lujie Liu, Yu-Rong Kang, Yanfeng Xiao
World Journal of Pediatrics (2021) Vol. 17, Iss. 4, pp. 394-399
Closed Access | Times Cited: 20

Showing 20 citing articles:

Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects
Mariam Farrag, Djedjiga Ait Eldjoudi, María González‐Rodriguez, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 38
Asprosin in the Paraventricular Nucleus Induces Sympathetic Activation and Pressor Responses via cAMP-Dependent ROS Production
Xiaoli Wang, Jing-Xiao Wang, Jun-Liu Chen, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12595-12595
Open Access | Times Cited: 29
Serum Asprosin Correlates with Indirect Insulin Resistance Indices
Małgorzata Mirr, Anna Braszak-Cymerman, Aleksandra Ludziejewska, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1568-1568
Open Access | Times Cited: 14
A study of the relationship between serum asprosin levels and MAFLD in a population undergoing physical examination
Dan Lv, Zepu Wang, Cuiqiao Meng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Molecular identification of asprosin and its function on glucose and lipid metabolism in grass carp (Ctenopharyngodon idella)
Guokun Yang, Mingyue Yin, Hao Wang, et al.
Aquaculture (2025), pp. 742221-742221
Closed Access
Circulating Asprosin and Neuregulin-4 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-analysis
Roshan Kumar Mahat, Vedika Rathore
Clinical Epidemiology and Global Health (2025), pp. 102041-102041
Open Access
Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the <b><i>FBN1</i></b> Gene, in Health and Disease
Mehmet Akif Ovalı, İbrahim Bozgeyik
Molecular Syndromology (2022) Vol. 13, Iss. 3, pp. 175-183
Open Access | Times Cited: 16
Asprosin: its function as a novel endocrine factor in metabolic-related diseases
Yang Zhang, Ping Yang, Xinliang Zhang, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 8, pp. 1839-1850
Closed Access | Times Cited: 3
Asprosin promotes vascular inflammation via TLR4-NFκB-mediated NLRP3 inflammasome activation in hypertension
Rui Ge, Jun-Liu Chen, Fen Zheng, et al.
Heliyon (2024) Vol. 10, Iss. 11, pp. e31659-e31659
Open Access | Times Cited: 3
Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling
B Zhang, Jinger Lu, Yuhua Jiang, et al.
Immunity Inflammation and Disease (2023) Vol. 11, Iss. 8
Open Access | Times Cited: 8
Circulating Asprosin Concentrations in Patients with Obesity and Carbohydrate Disturbances
Iveta Nedeva, Yavor Assyov, Vera Karamfilova, et al.
Hormone and Metabolic Research (2023) Vol. 55, Iss. 04, pp. 284-289
Closed Access | Times Cited: 7
Fibrillin-1 and asprosin, novel players in metabolic syndrome
Kim Summers, Stephen J. Bush, Margaret R. Davis, et al.
Molecular Genetics and Metabolism (2022) Vol. 138, Iss. 1, pp. 106979-106979
Closed Access | Times Cited: 11
Association of serum asprosin with metabolic dysfunction-associated fatty liver disease in older adult type 2 diabetic patients: a cross-sectional study
Junfang Cui, Yunfeng Liu, Mina Li, et al.
BMC Endocrine Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species
Chaowen Wang, Wenjing Zeng, Li Wang, et al.
Drug Development Research (2024) Vol. 85, Iss. 4
Closed Access | Times Cited: 2
Lack of correlation between asprosin serum levels and hyperphagic behavior in subjects with prader-Willi Syndrome
Maria Felicia Faienza, Mariangela Chiarito, Alessia Aureli, et al.
Journal of Endocrinological Investigation (2024)
Closed Access | Times Cited: 2
Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review
Zhengbin Zhang, Liwen Zhu, Ziqian Wang, et al.
Progress in Lipid Research (2023) Vol. 91, pp. 101240-101240
Closed Access | Times Cited: 6
Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus
Hongcui Diao, Xue Li, Yeqiu Xu, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 11, pp. 108614-108614
Closed Access | Times Cited: 5
Circulating levels of asprosin in children with obesity: a systematic review and meta-analysis
Yuwei Zhang, Yifei Zhang, Yang Bao, et al.
BMC Endocrine Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Circulating asprosin, irisin, and abdominal obesity in Chinese patients with type 2 diabetes mellitus: a case-control study
Guoping Hu, Wei Si, Qiang Zhang, et al.
Endokrynologia Polska (2022) Vol. 74, Iss. 1, pp. 55-62
Open Access | Times Cited: 6
Asprosin in nonalcoholic fatty liver disease and hypothyroidism: a case-control study
Mona Abdel-Latif Aboul-Seoud, Mohamed Kamal Ghitany, Ola Atef Sharaki, et al.
Alexandria Journal of Medicine (2024) Vol. 60, Iss. 1, pp. 265-273
Open Access
Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by ROS
Chaowen Wang, Wenjing Zeng, Li Wang, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top